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staging occurred, but were not different by study arm. 
Surgical resection rate was 49/71 in A, and 43/71 in B, with 
total margin status of 83 R0, 6 R1 and 3 R2, which by study 
arm was A 45:2:2 and B 38:4:1, p=0.6. Grades of AE, stoma-
related events, non-stoma-related surgical complications, 
and lab work were similar.  
Conclusions: Differences in surgical resection rates (69% vs. 
60%), R0 pathological margins (62% vs. 52%), and overall 
survival (63% and 55%) were not statistically significant, while 
relative safety was demonstrated for short-course RT. With a 
mean follow-up of 1.5 years, the preliminary results of this 
trial do not show a significant difference between 
randomization arms. An operability rate of 60% is important 
for a group of patients deemed inoperable/borderline at 
diagnosis in this group of developing countries.  
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Purpose/Objective: Single dose radiotherapy is standard 
treatment for painful bone metastases but the optimal dose 
remains incertain. This multi-centre, international, 
randomised radiotherapy trial compared a single dose of 8 Gy 
(n = 325) with that of 4 Gy (n = 326) to relieve pain arising 
from a single bone metastasis. 
Materials and Methods: Patients aged ≥ 18 years with bone 
pain, a histological diagnosis of malignancy, radiological 
evidence of bone metastasis at the site of pain and a life 
expectancy of ≥ 12 weeks were eligible. Exclusion criteria 
were myeloma, bone metastasis in previously irradiated sites, 
previous radioisotope treatment, or complicated bone 
metastasis. 
Pain relief at baseline, 4, 8, 12, 24 and 52 weeks was 
assessed using a Categorical Scale (CS) and a Visual Analogue 
Scale (VAS). The primary endpoint was the difference in the 
proportion of responders at 4 weeks.  
Results: There were 325 patients randomized to the 8Gy arm 
and 326 to the 4Gy arm with no significant difference in the 
distribution of demographic features or other co-variates 
between dose groups. 
Table 1 shows crude incidence of pain relief (all follow-ups) 
and prevalence at 4 weeks for CR, PR, NR and OR. There was 
a significant difference between dose groups when a global 
comparison was made for all follow-up times.. At the other 
intervals (8 to 52 weeks) both CRs and ORR was higher after 8 
Gy (statistically significant only at 8 weeks got CR; p = 0.03 
and at 8 and 52 weeks (p = 0.03 for ORTable 1 also 
summarises pain relief using the VAS method. Overall 
incidence and 4-week prevalence of pain relief was 
significantly higher after 8 Gy. 
The Kaplan-Meier actuarial rate (categorical scale) at 4 
weeks showed no significant difference in CR. The ORR was 
80% after 8 Gy compared to 68% after 4 Gy (log rank p = 
0.0015). 
A total of 117 of re-treatments were given of which 72 were 
in the 4 Gy dose group and 45 in the 8 Gy arm (p = 0.01). 
Table 1. Incidence (all follow-ups) and prevalence at 4 weeks 
of response to pain for patients with complete (CR), partial 
(PR), no (NR) and overall response (OR) using the categorical 
(CS) and visual analogue (VAS) scales. 
 
 
 
Conclusions: In a wide range of healthcare settings single 
dose radiotherapy is highly effective at achieving pain relief. 
Overall 8Gy is associated with a higher probability of pain 
relief from metastatic bone pain than 4Gy but there was still 
a high likelihood of pain response after the lower dose of 4 
Gy [71% (CS) and 82% VAS] although a significantly higher 
retreatment rate after 4Gy.  
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Purpose/Objective: Optimal radiotherapy utilization (RTU) 
rate has been studied for developed countries following an 
evidence-based, criterion-based method or based on 
assessment of current practice. In Australia, it has been 
determined to be 52.3% in 2003 later adjusted to 48.3% in 
2012.  
For developing countries, current estimates of the proportion 
of cancer patients who require radiotherapy can be 
estimated from the distribution of cancer types and stages. 
The purpose of this project was to assess the optimal RTU 
rates in 9 middle-income countries, following an evidence 
based method.  
Materials and Methods: Nine middle-income countries were 
selected to participate in this assessment.  
International guidelines were reviewed for external beam 
radiotherapy indications. Epidemiological data on the 
proportion of new cases of cancer with indication for 
radiotherapy specifically for the 9 target countries were 
identified. Indications and epidemiological data were merged 
to develop an optimal radiotherapy utilisation tree following 
the Collaboration for Cancer Outcomes Research and 
Evaluation (CCORE) method. Univariate and Monte Carlo 
simulations were used in sensitivity analysis. Globocan-2012 
lists 27 tumour types and there is a difference between the 
total for the individual tumour sites and the total number of 
cancers reported overall. The database does not report a 
separate ‘unknown’ category. The difference between the 
total cancer cases and the sum of the 27 identified cancer 
types is a combination of ‘other’ and ‘unknown’ cancers. 
‘Other’ and ‘unknown’ are split roughly 50:50 in Australia 
where 'other' has an optimal RTU rate of 19% and 'unknown' of 
61%. The average is thus 40%. We have assumed this is the 
same in the 9 target countries. It is probably an 
underestimate as there are likely to be higher proportions of 
unknown in middle income countries.  
This project also includes a prospective direct assessment of 
the actual RTU rates in these countries and the results will be 
reported separately. 
Results: The optimal overall RTU rates found for the target 
countries were: Costa Rica 47%, Ghana 50%, Malaysia 52%, 
Philippines 52%, Romania 51%, Serbia 53%, Slovenia 48%, 
Tunisia 54% and Uruguay 51%. The mean value was 51%.  
There was a difference of 7% between the lowest optimal 
RTU in Costa Rica (47%) and the highest in Tunisia (54%). This 
difference may be due to the incidence of three types of 
cancers treatable with radiotherapy and which have a lower 
incidence in Costa Rica than in Tunisia: bladder (1.8% vs. 
6.5%), lung (6.6% vs. 20.0%) and nasopharynx (0.8% vs. 3.8%). 
27.4% of all cancers in Ghana were cervix ca. with colorectal 
1.7%. However, the category 'other and unknown' in Ghana 
was 11.5% probably reflecting issues with cancer registration. 
Conclusions: The optimal RTU rate in this group of 9 middle-
income countries did not differ significantly from that found 
in higher income countries. 
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Purpose/Objective: The IAEA is assessing the current 
capacity and quality of radiotherapy (RT) services in post-
Soviet countries. We can now report on the current 
infrastructure in 12 countries in terms of number of facilities, 
equipment and staffing. The countries are: Armenia, 
Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, 
Moldova, Russian Federation, Tajikistan, Turkmenistan, 
Ukraine and Uzbekistan. 
Materials and Methods: In June 2012, Country Coordinators 
(CC) were identified. The CC had to provide: [1] 
infrastructure and quality indicators (QI) on their respective 
country, [2] infrastructure and QI on their own RT centre and 
[3] infrastructure and QI on other RT centres in their country. 
The survey questionnaire was adapted from two validated 
sets of QI for RT. 
The third and final phase of the Project consists of collection 
and analysis of QI on most RT centres in these 12 countries 
and this will be reported separately. 
Results: The overall data on RT infrastructure of 12 countries 
as reported by the CCs is presented in Table 1. 
The total number of RT centres is 250 with the Russian 
Federation having 144 centres, and Ukraine 52. 
The calculated number of TT machines/1M inhabitants was 
2.1 but varied widely from 0.1 in Tajikistan to 2.8 in the 
Russian Federation. The calculated number of TT machines 
per 1000 new cases/year was 0.8 but varied from 0.14 in TAJ 
to 1 in Turkmenistan, 0.77 in RUS and 0.75 in UKR. 
The organization of RT services usually includes a leading 
cancer centre with research capacity, large RT centres in 
large cities and smaller provincial centres. The group 
presents heterogeneity in that some metropolitan centres 
operate with modern equipment, while the majority rely on 
stand-alone Cobalt-60 machines. 
Assessment of staff levels was challenging since countries use 
professional designations and tasks which do not correspond 
to those in the west. In some countries, a 'radiologist' is 
licensed to read imaging studies, deliver radiotherapy and 
practice nuclear medicine. The profession of radiation 
therapist (RTT) is not well defined and the training path is 
minimal. The operation of treatment machines is done by 
